section name header

Basics

Clinical Manifestations

Diagnosis

Diagnosis-icon.jpg Differential Diagnosis

Cutaneous Squamous Cell Carcinoma (see later Discussion)
  • An AK may be indistinguishable from a squamous cell carcinoma.

  • Untreated, squamous cell carcinoma becomes indurated, with a tendency to ooze, ulcerate, or bleed.

Basal Cell Carcinoma (see later Discussion)
  • Classically, this lesion is a pearly, shiny papule with telangiectasias.

  • It may be indistinguishable from actinic keratosis, particularly when it is small, ulcerated, manipulated, or pigmented.

Verruca Vulgaris (Wart)
  • May be indistinguishable from an AK.

Seborrheic Keratosis (see Chapter 30: Benign Cutaneous Neoplasms)
  • Has a “stuck-on” appearance and may occur in areas not exposed to the sun.

  • Most often more darkly pigmented than AKs.

  • May be indistinguishable from an AK.

Chondrodermatitis Nodularis Helicis (see Chapter 30: Benign Cutaneous Neoplasms)
  • Often confused with AKs on the helix of the ears.

  • Always tender.

  • Arise on less sun-exposed sides of helices (lateral rim of helix).

Management-icon.jpg Management

  • Prevention begins with educating the patient to limit sun exposure by using sunscreens and wearing protective clothing.

Destructive Methods
  • Liquid nitrogen (LN2) is the traditional mainstay of treatment for AKs. LN2 is most useful when lesions are few in number. It is applied to individual lesions for 3 to 5 seconds.

  • For thick, hyperkeratotic lesions, a shave biopsy followed by electrocautery or electrocautery alone may be performed.

Patient Applied
Immunotherapy
  • Imiquimod (Aldara) 5% cream is a local inducer of interferon. It is applied twice weekly to involved skin for 16 weeks until a response similar to that described with 5-FU agents is elicited.

  • Imiquimod activates immune cells through a toll-like receptor. Activated cells secrete cytokines (primarily interferon- [INF-], interleukin-6 [IL-6], and tumor necrosis factor- [TNF-]) that leads to activation of the adaptive immune system. Other cell types activated by imiquimod include natural killer cells, macrophages, and B-lymphocytes.

  • Besides actinic keratoses, imiquimod has been approved for the treatment of superficial basal cell carcinomas (see below), Bowen disease (squamous cell carcinoma in situ), as well as genital warts (see Chapter 28: Sexually Transmitted Diseases).

  • Zyclara (imiquimod) cream, 2.5% and 3.75%, available in pump dispensers, are less concentrated imiquimod cream preparations that only need to be applied over the course of a shorter period of 2 weeks on and 2 weeks off for 2 months.

Chemotherapy
  • Topical application of Efudex, a 5-fluorouracil (5-FU) 5% cream, is used when lesions are too numerous to treat individually.

  • 5-FU interferes with the synthesis of DNA; it destroys dysplastic cells and spares normal cells. Enough medication is applied to cover the entire area with a thin film. This is done twice daily for 2 to 4 weeks for facial lesions. Other body sites require longer treatment (e.g., 6 to 8 weeks for the arms).

  • Alternatively, a 0.5% 5-FU cream (Carac) may be applied only once daily. This preparation is less irritating than the 5-FU 5% agents.

  • During treatment with 5-FU, lesions become increasingly red and crusted, and subclinical lesions become visible. This situation can result in a very red, disfiguring complexion; however, if the patient completes the treatment, lesions usually heal within 2 weeks of stopping treatment, the skin becomes smooth, and the majority of the actinic keratoses are gone (Fig. 31.12A,B).

Other Treatments
  • Photodynamic therapy can be used to treat multiple actinic keratoses. In this treatment, topical 5-aminolevulinic acid accumulates preferentially in the dysplastic cells. On exposure to irradiation with light of the appropriate wavelength, oxygen-derived free radicals are generated, and cell death results.

  • Chemical peels and dermabrasion are also used in patients with numerous facial actinic keratoses.

  • Diclofenac sodium 3% (Solaraze) gel is a nonsteroidal anti-inflammatory preparation that has been introduced as a topical treatment for actinic keratoses. These agents appear to be less irritating than the standard 5-FU products and Aldara, however, they are less effective.

  • Ingenol mebutate 0.015% and 0.05% gel (Picato), derived from the sap of the plant Euphorbia peplus, is an inducer of cell death via mitochondrial swelling and a secondary immune response via activation of protein kinase C delta.

    • For the face and scalp the 0.015% gel is used for 3 consecutive days.

    • For the trunk and extremities the 0.05% gel is used for 2 days.

    • The most common side effects are skin redness, flaking/scaling, crusting and swelling.

Helpful-Hint-icon.jpg Helpful Hints

  • Because actinic keratoses are more often easily felt than seen, the clinician should run ungloved fingers over the patient's skin to detect all lesions.

  • Sunscreens should also be applied to the lower lip to prevent actinic cheilitis.

  • Topical 5-FU treatment can be likened to using a “smart bomb” in which the “bomb” (in this case 5-FU) targets only the “enemy” (the rapidly growing dysplastic cells).

  • Imiquimod (Aldara, Zyclara) cream may “immunize” patients against their own dysplastic keratinocytes.

  • When treating with multiple AK lesions over large areas of skin, field-directed treatment with a topical agent is most effective.

SEE PATIENT HANDOUTS “Actinic Keratosis” and “Sun Protection Advice” IN THE COMPANION eBOOK EDITION.

Other Information

Histopathology